Correction to: Pharmacokinetic and Pharmacodynamic Modeling to Optimize the Dose of Vestronidase Alfa, an Enzyme Replacement Therapy for Treatment of Patients with Mucopolysaccharidosis Type VII: Results from Three Trials

[1]  C. Whitley,et al.  A novel Blind Start study design to investigate vestronidase alfa for mucopolysaccharidosis VII, an ultra-rare genetic disease. , 2018, Molecular genetics and metabolism.

[2]  Karen Jacobs,et al.  A novel, randomized, placebo-controlled, blind-start, single-crossover phase 3 study to assess the efficacy and safety of UX003 (rhGUS) enzyme replacement therapy in patients with MPS VII , 2017 .

[3]  V. Gladyshev,et al.  Gene expression signatures of human cell and tissue longevity , 2016, npj Aging and Mechanisms of Disease.

[4]  W. Sly,et al.  Clinical course of sly syndrome (mucopolysaccharidosis type VII) , 2016, Journal of Medical Genetics.

[5]  A. Shaywitz,et al.  Immunogenicity of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients With Morquio A Syndrome: Results From MOR-004, a Phase III Trial. , 2015, Clinical therapeutics.

[6]  W. Sly,et al.  First human treatment with investigational rhGUS enzyme replacement therapy in an advanced stage MPS VII patient. , 2015, Molecular genetics and metabolism.

[7]  A. Shaywitz,et al.  Pharmacokinetic and Pharmacodynamic Evaluation of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients with Morquio A Syndrome , 2014, Clinical Pharmacokinetics.

[8]  Durval Damiani,et al.  Bomba de infusão de insulina em diabetes melito tipo 1 , 2006 .

[9]  C. Eng,et al.  A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome) , 2006, Genetics in Medicine.

[10]  J. Wittes,et al.  Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. , 2006, The Journal of pediatrics.

[11]  J. Hopwood,et al.  Pharmacokinetic profile of recombinant human N‐acetylgalactosamine 4‐sulphatase enzyme replacement therapy in patients with mucopolysaccharidosis VI (Maroteaux–Lamy syndrome): a phase I/II study , 2005, Acta paediatrica (Oslo, Norway : 1992). Supplement.

[12]  Joseph Muenzer,et al.  Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). , 2004, The Journal of pediatrics.

[13]  W. Sly,et al.  Murine mucopolysaccharidosis type VII: The impact of therapies on the clinical course and pathology in a murine model of lysosomal storage disease , 1998, Journal of Inherited Metabolic Disease.

[14]  S. Brodie,et al.  A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies. , 2001, American journal of human genetics.

[15]  J. Belmont,et al.  Enzyme-replacement therapy in mucopolysaccharidosis I. , 2001, The New England journal of medicine.

[16]  W. Sly,et al.  Enzyme replacement therapy for murine mucopolysaccharidosis type VII leads to improvements in behavior and auditory function. , 1998, The Journal of clinical investigation.

[17]  W. Sly,et al.  Enzyme Replacement with Recombinant β-Glucuronidase in Murine Mucopolysaccharidosis Type VII: Impact of Therapy during the First Six Weeks of Life on Subsequent Lysosomal Storage, Growth, and Survival , 1996, Pediatric Research.

[18]  D. Brooks,et al.  Enzyme replacement therapy in a feline model of Maroteaux-Lamy syndrome. , 1996, The Journal of clinical investigation.

[19]  W. Sly,et al.  Beta glucuronidase deficiency: report of clinical, radiologic, and biochemical features of a new mucopolysaccharidosis. , 1973, The Journal of pediatrics.